| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9676b81bf60ff9772f2d479031685347 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-577
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2012-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c635e922a1495847403f6d5e2845c5b9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_49585c95644e0dae9b466ced81aa67ff
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9b343eaece0bd67e98b3334663aa606b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d9933bb6905a88db18d69d57c6611f1c |
| publicationDate |
2012-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2012244391-A1 |
| titleOfInvention |
Anti-ILT7 antibody |
| abstract |
Abstract An antibody binding to IPC was obtained by using an animal cell in which a cell membrane protein associatable with ILT7 was co-expressed as an immunogen. The antibody of the invention has a high specificity which allows immunological distinction between other ILT family molecules and ILT7. The anti-ILT7 antibody of the invention bound to IPC and inhibited the activity thereof. With the anti-ILT7 antibody of the invention, the IPC activity can be inhibited and an interferon-related disease can be treated or prevented. ILT7 expressionismaintainedeveninIPCinthepresenceof IFNa. Therefore, an inhibitory action of IPC activity by the anti-ILT7 antibody can be expe cted even in an autoimmune disease patient with an increased production of IFNax. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11072652-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11673950-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3426298-A4 |
| priorityDate |
2005-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |